ADVFN Logo

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

OVB Ovoca Bio Plc

0.70
0.00 (0.00%)
28 Mar 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Ovoca Bio Plc LSE:OVB London Ordinary Share IE00B4XVDC01 EUR0.125 (CDI)
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 0.70 0.60 0.80 0.70 0.70 0.70 26,313 08:00:01
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Pharmaceutical Preparations 1.46M -5.61M -0.0688 -0.10 570.95k
Ovoca Bio Plc is listed in the Pharmaceutical Preparations sector of the London Stock Exchange with ticker OVB. The last closing price for Ovoca Bio was 0.70p. Over the last year, Ovoca Bio shares have traded in a share price range of 0.65p to 14.25p.

Ovoca Bio currently has 81,563,806 shares in issue. The market capitalisation of Ovoca Bio is £570,947 . Ovoca Bio has a price to earnings ratio (PE ratio) of -0.10.

Ovoca Bio Share Discussion Threads

Showing 1401 to 1424 of 1425 messages
Chat Pages: 57  56  55  54  53  52  51  50  49  48  47  46  Older
DateSubjectAuthorDiscuss
01/3/2024
14:32
hTtps://www.proactiveinvestors.co.uk/companies/news/946551/how-futura-medical-turned-med3000-into-a-near-billion-pound-opportunity-946551.htmlWhy haven't OVB turned the placebo nasal spray from their failed study into a similar 'near billion pound opportunity'?
mdi
01/3/2024
12:20
Why don’t Ovoca Bio just copy the Futura Medical strategy and seek to get the placebo spray from their failed study just approved as a ‘clinically proven’ medical device spray? Its worked for FUM on paper .



Futura have a market Cap of over £119m from generating less then £4m in sales from marketing their placebo as ‘clinically proven’.

mdi
02/2/2024
11:10
As I had difficulty asking questions at the OVB AGM I sent some later by email.

Here are their responses which might be of interest.

Bear in mind I received their email below on 4th December so it is a couple of months old:

[JT 2] Clearly the recent Australian / New Zealand Orenetide trial results were extremely disappointing. It would seem to me that there has either been a flaw in previous trials or in this recent one. Which one is it?
[OVB] We strongly disagree that the disappointing results of a recent study mean that there is a flaw in this or the previous studies. Clinical studies are very complex scientific process with risks and uncertain outcome, despite any previous results. This was disclosed in Ovoca’s Re-Admission Document for the Proposed Acquisition of IVIX (Part 2 “Risk factors”, “RISKS RELATING TO THE ENLARGED GROUP AND THE SECTOR IN WHICH IT OPERATES” at p. 19-20):
“…Clinical testing is expensive and can take many years to complete and its outcome is inherently uncertain. Failure can occur at any time during the clinical trial process… The results of … earlier clinical trials may not be predictive of the results of later stage clinical trials. For example, the results generated to date in … Phase I or Phase II clinical trials for the Enlarged Group’s product candidate does not ensure that later clinical trials will demonstrate similar results. Product candidates in later stages of clinical trials may fail to show the desired safety and efficacy traits despite having progressed through pre-clinical studies and initial clinical trials…”
Unfortunately, it seems that this scientific risk has been realized.

[JT 3] Who oversaw the previous Russian Orenetide (BP-101) trials? Was it the management of IVIX?
[OVB] The previous Russian Orenetide (BP-101) trials were administrated by one of the leading Russian Contract Research Organizations (CRO) – OCT Clinical Trials. Trials Sponsor oversight (which is mandatory according to ICH GCP standard on clinical trials) was done by the management of IVIX. This is public information, but disclosed in the Russian clinical trials registry (however we have checked – automated page translation into English is available in the Chrome browser, and we assume it should be available in other major browsers).
Also, public information is available in the Clinicaltrials.gov registry: hxxps://www.clinicaltrials.gov/study/NCT03463707.

[JT 4] Is there any future at all for Orenentide?
[OVB] For the moment we are not ready to make any conclusions – study report is still in process, and additional internal assessments are ongoing. The Company will determine the appropriate future strategy regarding the development of Orenetide, including whether the Company can and should continue with its development of this product.

[JT 5] What is the future strategy for Ovoca Bio now?
[OVB] Again, we are assessing the Orenetide trial results and any implications this may have for the wider strategy of the Company, including a number of potential strategies. We will keep shareholders informed on any developments as and when appropriate. Please keep in mind that while answering to this question we are limited by AIM rules on disclosure of material and insider information, so our reply may not contain any significant comments / material updates beyond anything that already has been published via RNS.

jimtech
23/1/2024
07:44
Great you finally get a RNS and it's a pointless holding RNS from months ago.
dave4545
21/1/2024
11:09
Almost 5 months and not a word from the company. Would have thought this was plenty of time to decide if to stick or twist with orenetide.
dave4545
08/1/2024
08:59
This is only just the start.
Covid stocks are now all the rage again.

luckyabbeygale
04/1/2024
23:08
It is okay to invest this way when one has a lot of spare money for other stocks.

My biggest regret today was not selling some of my non moving shares to invest into Angel first thing at 17p.

However I managed to buy £4,000 worth and most likely they be worth more than double tomorrow.

I do have a very good feeling about this Ovoca and it is going to take some time, but it will be worth it in the end.

luckyabbeygale
04/1/2024
11:45
You paid all time low my style of investing.

Even if they give up on Orenetide there is still a very attractive cash shell route here and they still have Russian assets wether or not they can extract any money from them remains a long shot but they could take a hit and get something for them

dave4545
04/1/2024
11:04
Wow I am going to take it. As this seems to good an opportunity to miss.

I am in for 142277 at 0.84p.

luckyabbeygale
04/1/2024
08:20
3 months now not a peep, surely by now they must know wether to stick or twist.

0.85p offer online, absolutely dead now which you can expect.

dave4545
21/12/2023
08:26
Another stock desperate for a update.

I'm still holding, the size used to be worth a few quid but now it's a few k so
I'll leave it and see if the company becomes a cash shell.

But dropping on any sale on L2 atm because in this market there is just no support for dead stocks like this with no news no matter how cheap they look and this one is now valued way below cash levels but what is cash burn now.

Not worth selling if you hold still imho not worth averaging down either though

dave4545
05/12/2023
02:13
The Codger,this company lost over £5 million in 2022 financial year so probably has very little funds left now.
bri15
30/11/2023
11:44
Wtf are you on mate?obviously sniffing something
the codger
30/11/2023
09:56
Will the mugs on the BOD actually admit today that they were duped in the initial Russian trials, or will they keep stringing everyone along for as long as they can? All they need to do is open source the data from the trials and let some stats students loose on it to give a good indication of how likely it is to be genuine...
esmith3
30/11/2023
07:19
Agm today.company will have to update on strategy going forward. Otherwise the cashshell option is looming.
the codger
02/11/2023
08:32
No brainer at this level. Cash double of market value.
the codger
25/10/2023
19:02
Somebody got a excellent price today 1.2p or less.
dave4545
24/10/2023
20:10
wow £937k market cap

Despite the setback I think this is becoming heavily oversold but in this market most stocks are with no buyers out there and prices getting slashed on just a fraction of sales it would take previously to knock it down.

dave4545
19/9/2023
15:11
Shameless ramper dave4545 still ramping this one. As soon as there is a spike, he is going to dump
optmist
12/9/2023
07:16
£1.5 mil market cap recent cash £2.2 mil

Lots of tax losses, if they give up on the drug it could be a very attractive cash shell.

Still they might find a reason for such poor trial results and continue who knows.

Just think it's a fraction oversold now

dave4545
05/9/2023
10:43
More carnage. Hope everyone keeps away from dave4545 advice
optmist
01/9/2023
14:55
I just thought Id post it from the other site.
Made me think a bit about it.
Cheers for the replies.

recordz
01/9/2023
14:39
Interesting H
dave4545
01/9/2023
14:25
"a bit strange"

Sub 2020 yes...After 2021 no

Look at the data in the covid vaccine trials and they got approval...shocking !

So who knows who is telling the truth and who is lying here when it comes to this trial and the old Russian one from 2017

dave4545
Chat Pages: 57  56  55  54  53  52  51  50  49  48  47  46  Older

Your Recent History

Delayed Upgrade Clock